本文選題：乳腺癌 + HMGB1��； 參考：《武漢大學(xué)》2015年博士論文

【摘要】：第一部分高遷移族蛋白HMGB1的表達(dá)與人乳腺癌細(xì)胞放射敏感性的關(guān)系研究目的：研究HMGB1的表達(dá)對(duì)人乳腺癌細(xì)胞放射敏感性的影響。方法：構(gòu)建人乳腺癌MCF-7-sh-HMGB1及陰性對(duì)照模型MCF-7-NC穩(wěn)轉(zhuǎn)細(xì)胞模型。將shRNA進(jìn)行合成克隆入pGPU6/GFP/Neo shRNA載體中,將合成之后的載體命名為pGPU6/GFP/Neo-HMGB 1和pGPU6/GFP/Neo-shNC。HMGB1低表達(dá)和陰性對(duì)照穩(wěn)定轉(zhuǎn)染細(xì)胞系采用600ug/ml G418篩選5周,挑選克隆擴(kuò)增獲得,獲得的穩(wěn)定轉(zhuǎn)染細(xì)胞命名為MCF-7-shHMGB1和MCF-7-NC,采用RT-PCR和WB檢測(cè)其HMGB1的干擾效率,克隆形成實(shí)驗(yàn)檢測(cè)MCF-7-shHMGB1和MCF-7-NC細(xì)胞系的放射敏感性。結(jié)果：穩(wěn)定轉(zhuǎn)染細(xì)胞系的熒光純度為99%,MCF-7-sh-HMGB1與陰性對(duì)照組MCF-7-NC和空白親本組相比,mRNA相對(duì)表達(dá)量為(0.12975+0.0314)vS.(0.9625±0.0476) vs.(1)。.HMGB干擾后其mRNA表達(dá)為親本的12.5%,親本細(xì)胞與MCF-7-NC間無(wú)明顯差異；蛋白表達(dá)方面HMGB1顯著低于MCF-7-NC組,克隆形成顯示HMGB1干擾組的放射敏感性顯著提高,MCF-7-NC和MCF-7-shHMGB1的F2為(0.7756±0.0016) vs. (0.5732±0.0031) (p0.01); DO 為(2.7555±0.0810) vs. (2.4807±0.0331*) (p0.05); Dq為(3.1689±0.1431) vs. (0.7225±0.0210*) (p0.05)。結(jié)論：成功構(gòu)建了人乳腺癌MCF-7-sh-HMGB1及MCF-7-NC穩(wěn)轉(zhuǎn)細(xì)胞模型,MCF-7-shHMGB1穩(wěn)定下調(diào)HMGB1的表達(dá),MCF-7-NC無(wú)明顯下調(diào)；干擾HMGB1的表達(dá)導(dǎo)致MCF-7細(xì)胞的放射敏感性顯著增強(qiáng)。第二部分下調(diào)IMGB1的表達(dá)增強(qiáng)了人乳腺癌細(xì)胞放射敏感性的機(jī)制研究目的：探討HMGB1調(diào)控人乳腺癌細(xì)胞放射敏感性的分子機(jī)制,為乳腺癌的防治提供新的有效靶點(diǎn),從而為臨床治療提供理論依據(jù)。方法：采用穩(wěn)定干擾細(xì)胞模型MCF-7-sh-HMGB1及陰性對(duì)照模型MCF-7-NC進(jìn)行機(jī)制研究,相對(duì)端粒長(zhǎng)度采用realtime-PCR,目的蛋白表達(dá)采用Western blot,端粒酶活性采用PCR-ELISA。細(xì)胞增殖采用CCK-8檢測(cè)。細(xì)胞周期與凋亡采用流式細(xì)胞術(shù)檢測(cè),DNA損傷灶點(diǎn)的表達(dá)采用免疫熒光-共聚焦檢測(cè)�；钚匝鮎OS采用活性氧檢測(cè)試劑盒(熒光法)檢測(cè)。結(jié)果：下調(diào)HMGB1的表達(dá)增加了MCF-7細(xì)胞的放射敏感性,減少了hTERT和cyclinD1的集聚。MCF-7、MCF-7-shHMGB1和MCF-7-NC的相對(duì)端粒長(zhǎng)度分別為0.8574±0.0812、0.6763±0.0610和1,MCF-7-shHMGB1組與MCF-7-NC相比,相對(duì)端粒長(zhǎng)度明顯縮短(***p0.001)；與MCF-7組相比結(jié)果也類(lèi)似(*p0.05)。MCF-7-NC與MCF-7-shHMGB1二者端粒酶活性分別為1.6155±0.1512和1.169±0.0924,干擾HMGB1后導(dǎo)致MCF-7端粒酶活性明顯下降(*p0.05),而且顯著抑制了細(xì)胞增殖。在未照射時(shí),MCF-7-NC和MCF-7-shHMGB1細(xì)胞的S期的比例分別為(44.090±5.78)%和(29.080±4.234)%；在6Gy照射后6h,12h,24h進(jìn)行檢測(cè),MCF-7-NC和MCF-7-shHMGB1細(xì)胞的G2/M分別為(29.790±3.291)%、(23.324±4.580)%、(28.592±2.673)%VS(34.293±4.231)%、(31.959±3.265)%、(35.653±5.297)%,兩者差異具有顯著性意義,而其余細(xì)胞周期間無(wú)明顯差異。MCF-7-NC和MCF-7-shHMGB1的凋亡比例分別為(5.00±0.848)%和(25.500±1.272)%,下調(diào)HMGB1增加了凋亡水平(**p0.01)。在早期階段,HMGB1也參與了活性氧的調(diào)控。HMGB1通過(guò)改變端粒結(jié)合蛋白的水平來(lái)調(diào)控端粒穩(wěn)態(tài),如TPP1、TRF1、TRF2。HMGB1的下調(diào)同時(shí)抑制了ATM和ATR信號(hào)通路。結(jié)論：以上結(jié)果顯示下調(diào)HMGB1的表達(dá)破壞了人乳腺癌的端粒穩(wěn)態(tài),增強(qiáng)了放射敏感性,抑制了DNA損傷修復(fù),抑制了細(xì)胞生長(zhǎng)、促進(jìn)其凋亡,HMGB1可能是人乳腺癌放射治療潛在的新靶點(diǎn)。第三部分人乳腺癌組織中HMGB 1的表達(dá)與臨床病理特征相關(guān)性分析目的：比較HMGB1在乳腺浸潤(rùn)性導(dǎo)管癌患者的腫瘤組織與癌旁組織中的表達(dá)差異,并分析HMGB1蛋白表達(dá)水平與病理分級(jí)、淋巴結(jié)轉(zhuǎn)移、總體預(yù)后等相關(guān)臨床病理特征的關(guān)系,為乳腺癌的治療尋找新的靶標(biāo)。方法：收集武漢大學(xué)中南醫(yī)院病理科存檔的72例乳腺癌患者的組織標(biāo)本切片,入組標(biāo)準(zhǔn)：我院腫瘤科2001-7至2011-8收治的存有完整蠟塊組織的首診乳腺癌患者；未行術(shù)前新輔助化療,所有患者均行病理診斷確診為浸潤(rùn)性導(dǎo)管癌；接受標(biāo)準(zhǔn)術(shù)后輔助治療；無(wú)其他部位原發(fā)腫瘤；隨訪時(shí)間截止為2013-1。利用免疫組化法檢測(cè)患者癌組織與癌旁組織中HMGB1的表達(dá)差異,并分析HMGB1蛋白的表達(dá)與乳腺癌患者的年齡、絕經(jīng)狀態(tài)、腫瘤大小、病理分級(jí)、激素受體水平、淋巴結(jié)轉(zhuǎn)移、M分期、總體生存狀態(tài)的相關(guān)性。Kaplan-Meier方法分析HMGB1蛋白的表達(dá)對(duì)累積生存率的影響。結(jié)果：HMGB1的陽(yáng)性表達(dá)與年齡、絕經(jīng)狀態(tài)、病理分級(jí)、雌激素受體狀態(tài)、HER-2受體狀態(tài)、淋巴結(jié)轉(zhuǎn)移分期及M分期無(wú)明顯相關(guān)性,與腫瘤的增殖能力、孕激素受體狀態(tài)正相關(guān),與累積生存率負(fù)相關(guān),具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論：HMGB1的表達(dá)與乳腺癌的增殖正相關(guān),其高表達(dá)促進(jìn)腫瘤生長(zhǎng),且與預(yù)后負(fù)相關(guān),但需要進(jìn)一步擴(kuò)大樣本量及延長(zhǎng)部分樣本的隨訪時(shí)間。
[Abstract]:Part 1 the relationship between the expression of high mobility group protein HMGB1 and the radiosensitivity of human breast cancer cells: Objective: To study the effect of HMGB1 expression on the radiosensitivity of human breast cancer cells. Methods: to construct human breast cancer MCF-7-sh-HMGB1 and negative control model MCF-7-NC stable cell model. ShRNA was synthesized and cloned into pGPU6/GFP/N In the EO shRNA carrier, the synthesized carrier was named pGPU6/GFP/Neo-HMGB 1 and pGPU6/GFP/Neo-shNC.HMGB1 in the low expression and negative control stable transfection cell line for 5 weeks by 600ug/ml G418, and the cloned amplification was selected. The stable transfected cells were named MCF-7-shHMGB1 and MCF-7-NC, and RT-PCR and WB were used to detect the interference of HMGB1. Results: the radiosensitivity of MCF-7-shHMGB1 and MCF-7-NC cell lines was detected by cloning. Results: the fluorescence purity of the stable transfected cell line was 99%. Compared with the negative control group MCF-7-NC and the blank parent group, the relative expression of mRNA was (0.12975+0.0314) vS. (0.9625 + 0.0476) vs. (1)..HMGB interference, and the mRNA was expressed as a parent. In 12.5%, there was no significant difference between the parent cells and MCF-7-NC; the expression of protein HMGB1 was significantly lower than that of the MCF-7-NC group, and the clonal formation showed that the radiosensitivity of the HMGB1 interference group was significantly increased, the F2 of MCF-7-NC and MCF-7-shHMGB1 was (0.7756 + 0.0016) vs. (0.5732 + 0.0031) (P0.01), DO was (2.7555 + 0.0810) vs. (2.4807 + 0.0331*). Dq was (3.1689 + 0.1431) vs. (0.7225 + 0.0210*) (P0.05). Conclusion: successfully constructed the MCF-7-sh-HMGB1 and MCF-7-NC stable cell model of human breast cancer, MCF-7-shHMGB1 stably downregulated the expression of HMGB1, and there was no obvious downregulation of MCF-7-NC. The expression of interference HMGB1 resulted in a significant increase in the radiosensitivity of MCF-7 cells. Second down regulated the expression of IMGB1. The mechanism of enhancing the radiosensitivity of human breast cancer cells is to explore the molecular mechanism of HMGB1 regulating the radiosensitivity of human breast cancer cells, providing new effective targets for the prevention and control of breast cancer, and providing a theoretical basis for clinical treatment. Methods: a stable interfering cell model MCF-7-sh-HMGB1 and a negative control model MCF-7-N are used. The mechanism of C was studied. The relative telomere length was realtime-PCR, the expression of the target protein was Western blot, the activity of telomerase was detected by CCK-8 in PCR-ELISA. cell proliferation. The cell cycle and apoptosis were detected by flow cytometry. The expression of DNA damage focal point was detected by immunofluorescence confocal detection. Reactive oxygen ROS was tested by active oxygen test. Results: the expression of HMGB1 decreased the radiosensitivity of MCF-7 cells and reduced the concentration of hTERT and cyclinD1, and the relative telomere length of MCF-7-shHMGB1 and MCF-7-NC was 0.8574 + 0.0812,0.6763 + 0.0610 and 1 respectively. Compared with MCF-7-NC, the relative telomere length of MCF-7-shHMGB1 group was significantly shorter (***p0.001). Compared with the MCF-7 group, the telomerase activity of *p0.05.MCF-7-NC and MCF-7-shHMGB1 two were 1.6155 + 0.1512 and 1.169 + 0.0924 respectively. After interfering HMGB1, the telomerase activity of MCF-7 decreased significantly (*p0.05), and the cell proliferation was significantly inhibited. The S phase ratio of MCF-7-NC and MCF-7-shHMGB1 cells was 44.090, respectively (44.090). (+ 5.78)% and (29.080 + 4.234)%, 6h, 12h, 24h were detected after 6Gy irradiation. The G2/M of MCF-7-NC and MCF-7-shHMGB1 cells was (29.790 + 3.291)%, (23.324 + 4.580)%, (28.592 + 2.673)%VS (34.293 +%)%, (31.959 + 3.265)%, (31.959 + 3.265)%, and the difference was significant, but there was no significant difference between the remaining cell cycles. The apoptosis ratio of MCF-7-shHMGB1 was (5 + 0.848)% and (25.500 + 1.272)% respectively. Down regulation of HMGB1 increased the level of apoptosis (**p0.01). At the early stage, HMGB1 also participated in the regulation of reactive oxygen species (.HMGB1) by changing the level of telomere binding protein to regulate telomere homeostasis, such as TPP1, TRF1, TRF2.HMGB1 and inhibition of ATM and ATR signaling. Road. Conclusion: the above results show that the expression of HMGB1 down-regulation destroys the telomere homeostasis of human breast cancer, enhances radiosensitivity, inhibits the repair of DNA damage, inhibits cell growth, and promotes its apoptosis. HMGB1 may be a potential new target for radiation therapy in human breast cancer. The expression of HMGB 1 in third human breast cancer tissues and clinical pathology Objective: To compare the difference in the expression of HMGB1 in the tumor tissues of the patients with invasive ductal carcinoma of the breast, and to analyze the relationship between the expression of HMGB1 protein and pathological classification, lymph node metastasis, the overall prognosis and other related clinicopathological features, to find a new target for the treatment of breast cancer. Methods: collect the Wuhan big 72 cases of breast cancer in the pathology department of the central and southern hospital were examined for tissue specimens. The standard of the group: 2001-7 to 2011-8 of the Department of oncology in our hospital were treated with complete paraffin tissue for the first diagnosis of breast cancer patients; no preoperative neoadjuvant chemotherapy was performed. All patients were diagnosed with a dipped ductal carcinoma by pathological diagnosis; the standard postoperative adjuvant treatment was accepted. There was no primary tumor in other parts; the time of follow-up was 2013-1. using immunohistochemical method to detect the difference in the expression of HMGB1 in the cancer tissues and para cancerous tissues, and to analyze the expression of HMGB1 protein and the age, menopause, tumor size, pathological grade, hormone receptor level, lymph node metastasis, M staging, overall survival state of the patients with breast cancer. The correlation.Kaplan-Meier method was used to analyze the effect of HMGB1 protein expression on the cumulative survival rate. Results: the positive expression of HMGB1 was not associated with age, menopause, pathological grade, estrogen receptor status, HER-2 receptor status, lymph node metastasis staging and M staging, and was positively related to the proliferation of tumor and progesterone receptor status. The negative correlation of cumulative survival rate was statistically significant (P0.05). Conclusion: the expression of HMGB1 is positively related to the proliferation of breast cancer. Its high expression promotes tumor growth and has a negative correlation with the prognosis, but it is necessary to further expand the sample size and prolong the follow-up time of some samples.
【學(xué)位授予單位】：武漢大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2015
【分類(lèi)號(hào)】：R737.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 韓露,李光;生物標(biāo)記物與放射敏感性[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));2001年02期

2 徐永忠,鄭斯英,趙經(jīng)涌,朱巍,王洪海;熒光原位雜交技術(shù)檢測(cè)細(xì)胞內(nèi)在放射敏感性的研究[J];中華放射醫(yī)學(xué)與防護(hù)雜志;2002年02期

3 陳暑波;人類(lèi)放射敏感性的遺傳基礎(chǔ)[J];國(guó)外醫(yī)學(xué)(臨床放射學(xué)分冊(cè));2003年05期

4 高遠(yuǎn)紅,楊偉志,閆潔,袁智勇,劉新帆,徐國(guó)鎮(zhèn);“彗星”分析法檢測(cè)人癌裸鼠移植瘤的放射敏感性[J];中華放射腫瘤學(xué)雜志;2004年01期

5 馮瑞;柳永蕾;宋現(xiàn)讓;于金明;;分子水平預(yù)測(cè)腫瘤放射敏感性研究進(jìn)展[J];腫瘤學(xué)雜志;2008年08期

6 羅成基;;用抗血小板血清兩次重復(fù)注射對(duì)小鼠放射敏感性的影響[J];國(guó)外醫(yī)學(xué)(放射醫(yī)學(xué)分冊(cè));1980年01期

7 高汝貴;;環(huán)—磷酸腺甙同放射敏感性[J];日本醫(yī)學(xué)介紹;1983年05期

8 黎文亮,胡文華;人與狗外周血淋巴細(xì)胞放射敏感性的比較[J];軍事醫(yī)學(xué)科學(xué)院院刊;1986年01期

9 劉學(xué)成;輻射作用下的免疫狀態(tài)[J];國(guó)外醫(yī)學(xué)(放射醫(yī)學(xué)核醫(yī)學(xué)分冊(cè));1990年01期

10 楊星;腫瘤放射敏感性預(yù)測(cè)方法探索[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));1994年05期

相關(guān)會(huì)議論文 前10條

1 陳甲信;;基因芯片在腫瘤放射敏感性研究中的應(yīng)用[A];第七屆廣西腫瘤學(xué)術(shù)年會(huì)論文匯編[C];2003年

2 陳波;高黎;楊偉志;徐國(guó)鎮(zhèn);易俊林;黃曉東;李素艷;羅京偉;肖建平;;鼻咽癌放射敏感性與遠(yuǎn)期預(yù)后分析[A];2007第六屆全國(guó)放射腫瘤學(xué)學(xué)術(shù)年會(huì)論文集[C];2007年

3 鐘軍;熊戴群;羅輝;陳文學(xué);;腫瘤細(xì)胞放射敏感性與放射誘導(dǎo)凋亡關(guān)系的研究[A];2007第六屆全國(guó)放射腫瘤學(xué)學(xué)術(shù)年會(huì)論文集[C];2007年

4 柯青;朱圣明;楊賢子;駱志國(guó);;人喉鱗癌細(xì)胞輻射前后放射敏感性分子機(jī)制的比較[A];湖北省抗癌協(xié)會(huì)青年委員會(huì)第五屆青年學(xué)術(shù)論壇資料匯編[C];2013年

5 鐘曉鳴;;人宮頸癌細(xì)胞株放射敏感性體外研究[A];中華醫(yī)學(xué)會(huì)放射腫瘤治療學(xué)分會(huì)六屆二次暨中國(guó)抗癌協(xié)會(huì)腫瘤放療專(zhuān)業(yè)委員會(huì)二屆二次學(xué)術(shù)會(huì)議論文集[C];2009年

6 封巍;祝淑釵;鄭曉;王玉祥;王準(zhǔn);王鑫;;阻斷血管內(nèi)皮生長(zhǎng)因子表達(dá)對(duì)食管癌細(xì)胞放射敏感性的影響[A];2009年浙江省放射腫瘤治療學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2009年

7 閻小軍;王勝資;王紓宜;鄒麗芬;王雷;陸神斌;;鼻咽癌淋巴管及微血管生成與放射敏感性的相關(guān)性研究[A];第四屆中國(guó)腫瘤學(xué)術(shù)大會(huì)暨第五屆海峽兩岸腫瘤學(xué)術(shù)會(huì)議論文集[C];2006年

8 朱小東;蘇芳;曲頌;李齡;王琪;;不同放射敏感性鼻咽癌患者血清差異表達(dá)蛋白研究[A];中華醫(yī)學(xué)會(huì)放射腫瘤治療學(xué)分會(huì)六屆二次暨中國(guó)抗癌協(xié)會(huì)腫瘤放療專(zhuān)業(yè)委員會(huì)二屆二次學(xué)術(shù)會(huì)議論文集[C];2009年

9 王明國(guó);王中和;蔡以理;;MAb225調(diào)控口腔鱗癌細(xì)胞增殖和放射敏感性的實(shí)驗(yàn)研究[A];2004年口腔頜面腫瘤基礎(chǔ)研究學(xué)術(shù)研討會(huì)會(huì)議日程及論文集[C];2004年

10 楊笑曦;周福祥;楊壘;李錚;周云峰;;TRF2基因沉默對(duì)肺腺癌A549細(xì)胞放射敏感性的影響(摘要)[A];湖北省抗癌協(xié)會(huì)青年委員會(huì)第五屆青年學(xué)術(shù)論壇資料匯編[C];2013年

相關(guān)重要報(bào)紙文章 前2條

1 熙能;哪些腫瘤宜放療[N];大眾衛(wèi)生報(bào);2002年

2 湖南省腫瘤醫(yī)院 羅熙能;哪些腫瘤宜放療[N];大眾衛(wèi)生報(bào);2002年

相關(guān)博士學(xué)位論文 前10條

1 邰國(guó)梅;TIGAR調(diào)節(jié)自噬活性影響人腦膠質(zhì)瘤放射敏感性的機(jī)制研究[D];蘇州大學(xué);2016年

2 朱寶松;腫瘤相關(guān)巨噬細(xì)胞的自噬調(diào)節(jié)對(duì)胃癌放射敏感性的影響及機(jī)制研究[D];蘇州大學(xué);2016年

3 戴靜;端粒保護(hù)蛋白hPOT1對(duì)宮頸癌細(xì)胞放射敏感性的影響及其機(jī)制研究[D];武漢大學(xué);2014年

4 田浩;Hsa-miRNA-643調(diào)控Raf1影響NSCLC放射敏感性及侵襲轉(zhuǎn)移的初步研究[D];南京醫(yī)科大學(xué);2016年

5 柯少波;高遷移族蛋白HMGB1對(duì)端粒穩(wěn)態(tài)的調(diào)控及與放射敏感性的相關(guān)性研究[D];武漢大學(xué);2015年

6 陳功;microRNA參與腦膠質(zhì)瘤放射敏感性調(diào)節(jié)的機(jī)制研究[D];南京醫(yī)科大學(xué);2010年

7 李光;鼻咽癌放射敏感性的預(yù)測(cè)[D];中國(guó)醫(yī)科大學(xué);2002年

8 卜俊國(guó);表皮生長(zhǎng)因子受體對(duì)鼻咽癌細(xì)胞放射敏感性的影響[D];第一軍醫(yī)大學(xué);2007年

9 洪金省;磁共振彌散加權(quán)成像技術(shù)預(yù)測(cè)鼻咽癌放射敏感性的價(jià)值及其機(jī)制研究[D];福建醫(yī)科大學(xué);2012年

10 高遠(yuǎn)紅;Comet Assay檢測(cè)人癌細(xì)胞放射敏感性的研究[D];中國(guó)協(xié)和醫(yī)科大學(xué);2002年

相關(guān)碩士學(xué)位論文 前10條

1 邱子丹;siRNA干擾EGFR表達(dá)對(duì)食管鱗癌和腺癌放射敏感性影響[D];福建醫(yī)科大學(xué);2015年

2 姚亦帆;長(zhǎng)鏈非編碼RNA-X53654對(duì)肺上皮增殖、遷移和放射敏感性的影響及機(jī)制的研究[D];蘇州大學(xué);2015年

3 郭銀;尼妥珠單抗對(duì)食管鱗癌ECA-109細(xì)胞放射敏感性的影響及機(jī)制研究[D];河北醫(yī)科大學(xué);2015年

4 袁小鵬;抑制STAT3通路對(duì)人腦膠質(zhì)瘤細(xì)胞放射敏感性的影響及其作用機(jī)制研究[D];蘇州大學(xué);2015年

5 蘇玉飛;自噬誘導(dǎo)對(duì)大腸癌細(xì)胞放射敏感性的影響[D];蘇州大學(xué);2015年

6 鄭安平;COX-2、XRCC1及RASSF1在食管鱗癌中的表達(dá)及其與放射敏感性的研究[D];河南科技大學(xué);2015年

7 邱雋;SiRNA、Apigenin、LY294002、Wortmannin 抑制GLUT-1及PI3K/Akt信號(hào)通路影響喉癌放射敏感性體內(nèi)研究[D];浙江大學(xué);2015年

8 楊文影;抑制MUC1胞內(nèi)段對(duì)人肺腺癌A549細(xì)胞放射敏感性的影響及機(jī)制研究[D];重慶醫(yī)科大學(xué);2015年

9 李陽(yáng);人肺腺癌放射抗拒細(xì)胞株H1299R的建立及miR-183調(diào)控HIF-1α影響H1299R放射敏感性的初步研究[D];遵義醫(yī)學(xué)院;2016年

10 劉偉;長(zhǎng)鏈非編碼RNA-UCA1對(duì)大腸癌細(xì)胞放射敏感性的影響及其機(jī)制初探[D];蘇州大學(xué);2016年

，

本文編號(hào)：1914810